Indefinite Delivery Contract SPE2D223D0007

Award Date 2/15/23
Last Date to Order 2/14/28
Federal Agency
Medical Supply Chain
Ultimate Awardee
Gsms Inc.
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The federal contract IDV award SPE2D225D0011 is a single-award Indefinite Delivery Contract (IDC) held by Golden State Medical Supply, Inc., a for-profit pharmaceutical manufacturer and distributor based in Camarillo, California. The contract, which has a ceiling value of $17,851,362.78 and an ultimate completion date of April 16, 2030, was awarded on April 17, 2025 by the Defense Logistics Agency (DLA), a defense agency. Under this IDC, Golden State Medical Supply, Inc. will provide a wide...
The federal contract IDV award SPE2D223D0013 is a single-award Indefinite Delivery Contract valued at $3,988,286.45 and awarded to Golden State Medical Supply, Inc., a for-profit pharmaceutical manufacturer and distributor based in Camarillo, California. The contract, which does not utilize any set-asides, was awarded by the Medical Supply Chain division of the Defense Logistics Agency (DLA) with an ultimate completion date of September 26, 2028. The contract is focused on providing a wide range...
The federal contract IDV award SPE2D223D0006 was a single-award indefinite delivery contract awarded to Golden State Medical Supply, Inc., a pharmaceutical manufacturer and distributor based in Camarillo, California. The contract has a ceiling value of $13,436,082.40 and an ultimate completion date of March 5, 2028. This IDV contract is intended to provide a reliable supply of essential pharmaceutical products, such as omeprazole, metformin, sumatriptan, and levofloxacin, to support critical...
The federal contract IDV award SPE2D223D0012 was issued by the Defense Logistics Agency (DLA) to Golden State Medical Supply, Inc., a for-profit pharmaceutical manufacturer and distributor based in Camarillo, California. The contract is an Indefinite Delivery Contract with a ceiling value of $4,329,877.25 and a period of performance through October 17, 2028. Under this IDV, Golden State Medical Supply, Inc. will provide a wide range of essential pharmaceutical products, such as omeprazole,...
The federal contract IDV award SPE2D221D0127 was granted to Golden State Medical Supply, Inc., a for-profit pharmaceutical manufacturer and distributor based in Camarillo, California. The IDV has a ceiling value of $23,136,506.40 and was awarded on December 1, 2020 by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense. The IDV is designed to provide an uninterrupted supply of essential pharmaceutical products, including tablets and capsules for...
The federal contract IDV award SPE2D224D0004 was granted to Golden State Medical Supply, Inc., a for-profit pharmaceutical manufacturer and distributor based in Camarillo, California. The single-award, indefinite delivery contract has a ceiling value of $28,836,471.10 and an ultimate completion date of February 27, 2029. This contract is intended to provide an uninterrupted supply of essential pharmaceutical products, predominantly prescription medications, to federal healthcare facilities...
The federal contract IDV award SPE2D224D0005 is a single-award Indefinite Delivery Contract issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA), a defense agency, to the prime contractor Golden State Medical Supply, Inc. The contract has a total ceiling value of $20,495,935.00 and a period of performance through April 3, 2029. Under this IDV, Golden State Medical Supply, Inc. will provide a variety of pharmaceutical products to the Department of Veterans Affairs...
The key elements of this federal contract IDV award are as follows: The Defense Logistics Agency (DLA) awarded an Indefinite Delivery Contract (IDC) to Golden State Medical Supply, Inc., a for-profit pharmaceutical manufacturer and distributor based in Camarillo, California. The contract has a ceiling value of $6,883,760.65 and a period of performance through November 15, 2027. This single-award IDC is not designated as a set-aside. Under this IDC, Golden State Medical Supply has received...
The federal contract IDV award SPE2D224D0006 was granted to Golden State Medical Supply, Inc., a for-profit pharmaceutical manufacturer and distributor based in Camarillo, California. The $3,719,687.18 single-award IDV contract, which does not utilize any set-asides, was awarded by the Defense Logistics Agency (DLA) on July 10, 2024 with a completion date of July 9, 2029. The IDV contract is intended to establish a national supply source for the Department of Defense, Department of Veterans...
The Indefinite Delivery Contract awarded to Golden State Medical Supply, Inc. by the Defense Logistics Agency Troop Support Medical is a single-award contract to provide a range of pharmaceutical products to federal agencies including the Department of Veterans Affairs (VA), Department of Defense (DoD), Bureau of Prisons, and Indian Health Service (IHS). The contract has a potential value of $1 and a period of performance ending on January 9, 2024. The contract enables the government to issue...

The federal contract IDV award, SPE2D223D0007, is an indefinite delivery contract held by Golden State Medical Supply, Inc., a for-profit pharmaceutical manufacturer and distributor based in Camarillo, California. The contract, awarded by the Defense Logistics Agency (DLA), has a ceiling value of $17,621,453.20 and an ultimate completion date of February 14, 2028.

The contract is designed to provide an uninterrupted supply of essential pharmaceutical products, such as omeprazole, metformin, sumatriptan, and levofloxacin, to federal healthcare facilities, including the Department of Veterans Affairs (VA), Department of Defense (DoD), Bureau of Prisons, and Indian Health Service. The contract utilizes the VA and DoD Pharmaceutical Prime Vendor Programs to manage the distribution of these medications. The contract has a base period of one year with four one-year option periods, reflecting the government's need for a reliable and systematic approach to pharmaceutical procurement across multiple agencies.

Generated 8/5/25, 9:44 AM